MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, its first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut.

Company profile
Ticker
MNKD
Exchange
Website
CEO
Michael Castagna
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
133607736
MNKD stock data
News

MannKind: Q2 Earnings Insights
9 Aug 22
MannKind Q2 EPS $(0.11) Misses $(0.09) Estimate, Sales $18.90M Beat $15.62M Estimate
9 Aug 22
Earnings Scheduled For August 9, 2022
9 Aug 22
Earnings Outlook For MannKind
8 Aug 22
Jim Cramer Recommends Selling This Stock: 'No One Ever Likes Me To Say Anything Bad' About This Company
4 Aug 22
Press releases
MannKind Corporation Reports 2022 Second Quarter Financial Results
9 Aug 22
MannKind Corporation to Hold 2022 Second Quarter Financial Results Conference Call on August 9, 2022
2 Aug 22
MannKind Corporation to Participate in the BTIG Biotechnology Conference
1 Aug 22
Mannkind to Host Product Theater and Booth at the American Diabetes Association's 82nd Scientific Sessions in New Orleans, June 3-7
3 Jun 22
MannKind's Technosphere® Inhalation Platform Utilized in FDA-Approved Tyvaso DPI™
24 May 22
Investment data
Securities sold
Number of investors
Calendar
4 May 22
12 Aug 22
31 Dec 22
Financial summary
Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 67.24M | 67.24M | 67.24M | 67.24M | 67.24M | 67.24M |
Cash burn (monthly) | 18.98M | 15.06M | 8.67M | 8.01M | 6.08M | 5.6M |
Cash used (since last report) | 83.49M | 66.25M | 38.12M | 35.25M | 26.76M | 24.64M |
Cash remaining | -16.25M | 988.46K | 29.12M | 31.99M | 40.49M | 42.6M |
Runway (months of cash) | -0.9 | 0.1 | 3.4 | 4.0 | 6.7 | 7.6 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Jul 22 | Steven B. Binder | Common Stock, $0.01 Par Value | Buy | Acquire P | No | No | 2.93 | 791 | 2.32K | 728,997 |
31 Jul 22 | Michael Castagna | Common Stock, $0.01 Par Value | Buy | Acquire P | No | No | 2.93 | 3,147 | 9.22K | 2,084,486 |
31 Jul 22 | Stuart A Tross | Common Stock, $0.01 Par Value | Buy | Acquire P | No | No | 2.93 | 4,581 | 13.42K | 830,650 |
31 Jul 22 | Alejandro Galindo | Common Stock, $0.01 Par Value | Buy | Acquire P | No | No | 2.93 | 5,000 | 14.65K | 781,690 |
18 May 22 | David Thomson | Common Stock, $.01 Par Value | Payment of exercise | Dispose F | No | No | 3.19 | 6,001 | 19.14K | 747,213 |
Institutional ownership, Q1 2022
50.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 182 |
Opened positions | 25 |
Closed positions | 35 |
Increased positions | 55 |
Reduced positions | 45 |
13F shares | Current |
---|---|
Total value | 437.47M |
Total shares | 126.61M |
Total puts | 752K |
Total calls | 719.6K |
Total put/call ratio | 1.0 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 20.73M | $76.3M |
STT State Street | 14.7M | $54.11M |
Vanguard | 12.78M | $47.04M |
CVI Investments | 10.65M | $13.73M |
Avoro Capital Advisors | 8.8M | $32.38M |
Emerald Advisers | 5.68M | $20.89M |
FMR | 5.3M | $19.51M |
Geode Capital Management | 4.53M | $16.69M |
Emerald Mutual Fund Advisers Trust | 4.36M | $16.04M |
Flynn James E | 2.44M | $2.59M |
Financial report summary
?Risks
- Afrezza may only achieve a limited degree of commercial success. The continued commercialization and development of Afrezza will require substantial capital that we may not be able to obtain.
- If we fail as an effective manufacturing organization, we may be unable to support commercialization of Afrezza or Tyvaso DPI.
- If our suppliers fail to deliver materials and services needed for commercial manufacturing in a timely and sufficient manner or fail to comply with applicable regulations, and if we fail to timely identify and qualify alternative suppliers, our business, financial condition and results of operations would be harmed and the market price of our common stock and other securities could decline.
- If Afrezza or any other product that we develop does not become widely accepted by physicians, patients, third-party payers and the healthcare community, we may be unable to generate significant revenue, if any.
- If third-party payers do not cover Afrezza or any of our product candidates for which we receive regulatory approval, Afrezza or such product candidates might not be prescribed, used or purchased, which would adversely affect our revenues.
- We may need to raise additional capital to fund our operations.*
- We expect that our results of operations will fluctuate for the foreseeable future, which may make it difficult to predict our future performance from period to period.
- Our business, product sales, results of operations and ability to access capital could be adversely affected by the effects of health pandemics or epidemics, including the ongoing COVID-19 pandemic, in regions where we or third parties distribute our products or where we or third parties on which we rely have significant manufacturing facilities, concentrations of clinical trial sites or other business operations.*
- If we do not obtain regulatory approval of Afrezza in foreign jurisdictions, we will not be able to market Afrezza in such jurisdictions, which could limit our commercial revenues. We may not be able to establish additional regional partnerships or other arrangements with third parties for the commercialization of Afrezza outside of the United States.
- We may not be successful in our efforts to develop and commercialize our product candidates.*
- We have a history of operating losses. We expect to incur losses in the future and we may not generate positive cash flow from operations in the future.*
- We have a substantial amount of debt, and we may be unable to make required payments of interest and principal as they become due.*
- If we do not achieve our projected development goals in the timeframes we expect, our business, financial condition and results of operations will be harmed and the market price of our common stock and other securities could decline.*
- Afrezza or our product candidates may be rendered obsolete by rapid technological change.
- Continued testing of Afrezza or our product candidates may not yield successful results, and even if it does, we may still be unable to successfully commercialize our product candidates.
- If product liability claims are brought against us, we may incur significant liabilities and suffer damage to our reputation.*
- If we lose any key employees or scientific advisors, our operations and our ability to execute our business strategy could be materially harmed.
- Our ability to use net operating losses to offset future taxable income may be subject to limitations.
- Tax authorities may disagree with our positions and conclusions regarding certain tax positions, resulting in unanticipated costs, taxes or non-realization of expected benefits.
- We may undertake internal restructuring activities in the future that could result in disruptions to our business or otherwise materially harm our results of operations or financial condition.
- Our operations might be interrupted by the occurrence of a natural disaster or other catastrophic event.*
- We deal with hazardous materials and must comply with environmental laws and regulations, which can be expensive and restrict how we do business.
- Changes in funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.
- Our product candidates must undergo costly and time-consuming rigorous nonclinical and clinical testing and we must obtain regulatory approval prior to the sale and marketing of any product in each jurisdiction. The results of this testing or issues that develop in the review and approval by a regulatory agency may subject us to unanticipated delays or prevent us from marketing any products.
- If we do not comply with regulatory requirements at any stage, whether before or after marketing approval is obtained, we may be fined or forced to remove a product from the market, subject to criminal prosecution, or experience other adverse consequences, including restrictions or delays in obtaining regulatory marketing approval.
- We are subject to stringent, ongoing government regulation.
- Healthcare legislation may make it more difficult to receive revenues.
- Reports of side effects or safety concerns in related technology fields or in other companies’ clinical studies could delay or prevent us from obtaining regulatory approval for our product candidates or negatively impact public perception of Afrezza or any other products we may develop.
- If we are unable to protect our proprietary rights, we may not be able to compete effectively, or operate profitably.
- If we become involved in lawsuits to protect or enforce our patents or the patents of our collaborators or licensors, we would be required to devote substantial time and resources to prosecute or defend such proceedings.
- If our technologies conflict with the proprietary rights of others, we may incur substantial costs as a result of litigation or other proceedings and we could face substantial monetary damages and be precluded from commercializing our products, which would materially harm our business and financial condition.
- We may not obtain trademark registrations for our potential trade names.
- We may not be able to generate sufficient cash to service all of our indebtedness and commitments. We may be forced to take other actions to satisfy our obligations or we may experience a financial failure.
- Our stock price is volatile and may affect the market price of our common stock and other securities.*
- The future sale of our common stock or the exchange or conversion of our convertible debt into common stock could negatively affect the market price of our common stock and other securities.*
- Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.
- Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America are the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.
- Because we do not expect to pay dividends in the foreseeable future, you must rely on stock appreciation for any return on any investment in our common stock.
- Future sales of shares of our common stock in the public market, or the perception that such sales may occur, may depress our stock price and adversely impact the market price of our common stock and other securities.
- If other biotechnology and biopharmaceutical companies or the securities markets in general encounter problems, the market price of our common stock and other securities could be adversely affected.
Management Discussion
- ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
- Statements in this report that are not strictly historical in nature are “forward-looking statements” within the meaning of the federal securities laws made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth below in Part II, Item 1A Risk Factors and elsewhere in this Quarterly Report on Form 10-Q. The preceding interim condensed consolidated financial statements and this Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements and related notes for the year ended December 31, 2021 and Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in the Annual Report. Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they are made.
- We are a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Our lead product is Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, which was approved by the FDA in June 2014. We collaborate with a number of third parties to formulate their drugs on our Technosphere drug delivery platform. Since September 2018, we have been collaborating with United Therapeutics to develop an inhaled formulation of treprostinil known as Tyvaso DPI. In April 2021, United Therapeutics submitted an NDA to the FDA seeking approval of Tyvaso DPI. The NDA was resubmitted in December 2021 following a CRL in October 2021. The FDA is expected to complete its review of the pending NDA for Tyvaso DPI in May 2022.
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
absorption, accessible, adware, aimed, alleviate, assemble, assembled, assumption, attendant, benchmark, bound, broader, campaign, caption, cliff, climate, clofazimine, Cloud, Colorado, convened, credential, CRL, cyberattack, cybersecurity, deadline, deploying, deter, diminished, discovered, downturn, effectuate, encryption, endeavor, energy, ESG, expenditure, Extortion, extreme, fashion, France, geopolitical, grow, inquiry, land, leaseback, LUX, military, misconduct, misuse, molded, necessitate, network, occupancy, offline, Overnight, patch, phishing, portfolio, posture, Presidential, Pro, quantify, reliant, remit, residual, resubmitted, retaliatory, Russia, secondary, server, SOFR, SSP, stuffing, territory, theft, traditional, transmit, UKG, Ukraine, unlawful, unstable, vendor, Virginia, whichever
Removed:
accommodate, Accountability, adapted, Aid, AMSL, anesthesiologist, appeal, ASU, ATRA, audit, Australasian, Australia, automatic, BBA, belonging, blister, borrower, broadly, build, bundle, Canada, cancer, certified, Chase, combine, concealing, consented, corruption, covering, creation, crime, cyber, defraud, demonstration, deployment, directed, dismissed, divided, doubt, drawdown, drawn, dry, economically, electrical, engineering, equally, evidenced, executing, explosive, falsifying, Favored, foil, forgiven, freestanding, handling, harmful, hedging, imaging, informally, insolvent, intrusion, Issuer, joinder, joined, joint, JPMorgan, mandate, midst, mixture, motion, motivated, nation, nationwide, Northern, Obama, onset, open, Paycheck, payroll, Portability, PPP, preliminary, QrumPharma, qualifying, random, ranked, realization, recommending, reexamining, reliability, relief, removing, repealed, responsibility, ruling, satisfactory, SBA, semiannually, sequester, shared, Small, stay, subordinated, suitably, Supreme, target, targeted, tasked, taxation, Taxpayer, telecommunication, terrorism, tie, trillion, Trump, unconstitutional, unconstrained, unique, unnecessary, usability, utility, vested, vulnerable, waiver, war, website, word
Financial reports
Current reports
8-K
Other Events
25 May 22
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
23 May 22
8-K
Submission of Matters to a Vote of Security Holders
12 May 22
8-K
Mannkind Corporation Reports 2022 First Quarter Financial Results
4 May 22
8-K
Mannkind Corporation Reports 2021 Fourth Quarter and Full Year Financial Results
24 Feb 22
8-K
Other Events
18 Jan 22
8-K
Other Events
27 Dec 21
8-K
Results of Operations and Financial Condition
9 Nov 21
8-K
Entry into a Material Definitive Agreement
18 Oct 21
8-K
Entry into a Material Definitive Agreement
29 Sep 21
Registration and prospectus
S-3ASR
Automatic shelf registration
24 Feb 22
S-8
Registration of securities for employees
7 Aug 20
424B5
Prospectus supplement for primary offering
7 May 19
S-3
Shelf registration
29 Mar 19
424B5
Prospectus supplement for primary offering
20 Dec 18
424B5
Prospectus supplement for primary offering
19 Dec 18
S-8
Registration of securities for employees
7 Aug 18
S-8
Registration of securities for employees
4 Jun 18
424B5
Prospectus supplement for primary offering
5 Apr 18
424B5
Prospectus supplement for primary offering
27 Feb 18
Proxies
DEFA14A
Additional proxy soliciting materials
30 Mar 22
DEFA14A
Additional proxy soliciting materials
6 May 21
DEFA14A
Additional proxy soliciting materials
7 Apr 21
DEFA14A
Additional proxy soliciting materials
10 Apr 20
PRE 14A
Preliminary proxy
1 Apr 20
DEFA14A
Additional proxy soliciting materials
28 Mar 19
DEF 14A
Definitive proxy
28 Mar 19
Other
CT ORDER
Confidential treatment order
28 Oct 21
EFFECT
Notice of effectiveness
8 Apr 19
UPLOAD
Letter from SEC
3 Apr 19
CORRESP
Correspondence with SEC
2 Apr 19
CT ORDER
Confidential treatment order
30 Nov 18
CT ORDER
Confidential treatment order
12 Jun 18
CT ORDER
Confidential treatment order
5 Dec 17
EFFECT
Notice of effectiveness
13 Jul 17
CORRESP
Correspondence with SEC
11 Jul 17
UPLOAD
Letter from SEC
10 Jul 17
Ownership
4
MANNKIND / Steven B. Binder ownership change
1 Aug 22
4
MANNKIND / Michael Castagna ownership change
1 Aug 22
4
MANNKIND / Stuart A Tross ownership change
1 Aug 22
4
MANNKIND / Alejandro Galindo ownership change
1 Aug 22
4/A
MANNKIND / Alejandro Galindo ownership change
25 May 22
4
MANNKIND / Michael Castagna ownership change
20 May 22
4
MANNKIND / Joseph Kocinsky ownership change
20 May 22
4
MANNKIND / Alejandro Galindo ownership change
20 May 22
4
MANNKIND / Stuart A Tross ownership change
20 May 22
4
MANNKIND / Steven B. Binder ownership change
20 May 22
Patents
Utility
Formation of N-protected 3,6-bis-(4-aminobutyl)-2,5-diketopiperazine through a cyclic α-N-protected amino ester
31 May 22
A method for the synthesis of N-protected 3,6-aminoalkyl-2,5-diketopiperazines is provided.
Utility
Inhalable dry powder pharmaceutical composition
19 Apr 22
A method for treating hyperglycemia and/or diabetes in a subject is provided.
Utility
Catalysis of diketopiperazine synthesis
5 Apr 22
Provided is a method for the synthesis of N-protected 3,6-bis-[4-aminobutyl]-2,5-diketopiperazine including the step of heating a solution of ε-amino protected lysine in the presence of a catalyst selected from the group consisting of sulfuric acid, phosphoric acid, and phosphorus pentoxide.
Utility
Dry Powder Inhaler and System for Drug Delivery
17 Feb 22
A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided.
Utility
Microcrystalline Diketopiperazine Compositions and Methods
17 Feb 22
Disclosed herein are DKP microcrystals made by an improved method where they do not irreversibly self-assemble into microparticles.
Transcripts
2022 Q2
Earnings call transcript
10 Aug 22
2022 Q1
Earnings call transcript
6 May 22
2021 Q4
Earnings call transcript
25 Feb 22
2021 Q3
Earnings call transcript
10 Nov 21
2021 Q2
Earnings call transcript
12 Aug 21
2021 Q1
Earnings call transcript
13 May 21
2020 Q4
Earnings call transcript
25 Feb 21
2020 Q3
Earnings call transcript
4 Nov 20
2020 Q2
Earnings call transcript
5 Aug 20
2020 Q1
Earnings call transcript
6 May 20
Reddit threads
Daily Discussion Thread - August 9th, 2022
9 Aug 22
Daily Discussion Thread - May 5th, 2022
5 May 22
Daily Discussion Thread - May 4th, 2022
4 May 22
Picks for 2022-03-08
9 Mar 22
Daily Discussion Thread - February 24th, 2022
24 Feb 22
Daily Discussion Thread - February 23rd, 2022
23 Feb 22
Daily Discussion Thread - February 22nd, 2022
22 Feb 22
Daily Discussion Thread - February 21st, 2022
21 Feb 22
Daily Plays December 29, 2021
28 Dec 21
Daily Plays December 28, 2021
27 Dec 21